Red Light Holland Corp

Red Light Holland Corp

0.03
CAD
0.00
(0.00%)
-0.02EPS
18.42MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
0.01
Basic EPS, GAAP
- -
- -
-0.01
-0.04
-0.01
-0.02
-0.01
-0.01
-0.02
Free Cash Flow per Basic Share
- -
- -
-0.02
-0.02
-0.02
-0.01
-0.01
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.01
-0.01
0.1
0.08
0.07
0.05
0.04
0.03
0.03
Tangible Book Value per Share
-0.01
-0.01
0.1
0.08
0.06
0.05
0.04
0.03
0.02
Basic Weighted Avg Shares
196
196
211
351
373
395
401
417
452
Sales/Revenue/Turnover
- -
- -
- -
2
4
5
5
4
3
Operating Margin (%)
-1,660.28
- -
-4,187.71
-408.88
-125.4
-130.2
-85.15
-98.32
-142.31
Depreciation Expense
- -
- -
- -
1
1
1
1
- -
- -
Net Income, GAAP
- -
- -
-2
-14
-5
-8
-4
-6
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,660.28
- -
-1,482.41
-617.78
-136.67
-160.51
-81.75
-145.45
-225.31
Working Capital
-2
-1
33
25
20
14
11
9
8
LT Debt
- -
- -
1
- -
- -
- -
- -
- -
- -
Total Equity
-3
-1
34
29
26
20
17
11
18
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-45.95
-19.79
-33.07
-21.6
-41.63
-39.04

Capital Structure

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
423
426
614
Market Capitalization
8
11
18

Working Capital

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
14
12
11
Cash, Cash Equivalents & STI
10
9
8
Accounts Receivable, Net
1
- -
- -
Inventories
1
1
- -
Total Current Liabilities
3
3
3
Payables & Accruals
2
2
2
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-19.36%
-35.33%
Free Cash Flow
- -
12.21%
81.13%
Net Income, GAAP
- -
151.26%
50.96%
Sales/Revenue/Turnover
- -
415%
-15.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2
1
1
1
5
2026
1
1
1
1
4
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
-0.01
-0.01
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Todd Michael Shapiro
Full Time Employees
104
Sector
Process industries
Industry
Agricultural commodities/Milling
Address
1 Adelaide Street East Toronto ON Canada M5C 2V9
IPO Date
May 28, 2020
Business
Red Light Holland Corp. is actively involved in the cultivation, processing, and distribution of natural psilocybin truffles for the regulated adult-use market in the Netherlands. The company also engages in the production and sale of functional mushrooms and associated home cultivation kits across North America and Europe. Its diverse offerings extend to cannabidiol products, various cannabis seeds, specialty headshop items, and baked goods like muffins, cookies, and cakes. These products are marketed under prominent brand names such as iMicrodose, Maka, Happy Caps, and Mistercap, available through an expanding network of physical SmartShops and comprehensive online retail platforms. Headquartered in Toronto, Ontario, the company recently reported Q2 2025 revenue of $4.9 million, emphasizing strategic international expansion and the launch of Health Canada-approved functional mushroom gummies, alongside a new Bitcoin treasury strategy.

Company News

  • Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

  • Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property